Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drugs for Children.

S Ito1

  • 1Division of Clinical Pharmacology and Toxicology, Department of Paediatrics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.

Clinical Pharmacology and Therapeutics
|May 17, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prostaglandin E2-induced arachidonic acid release and catecholamine secretion from cultured bovine adrenal chromaffin cells.

Biochemical pharmacology·1992
Same author

Multiple projection of vagal non-myelinated afferents to the anterior insular cortex in rats.

Neuroscience letters·1992
Same author

Wear of denture teeth by use of metal plates. Part 3: Abrasive wear of posterior teeth and wear of opposing metal plates.

The Journal of Nihon University School of Dentistry·1992
Same author

Two sudden death cases of idiopathic ventricular tachycardia.

The Tokushima journal of experimental medicine·1992
Same author

A case of concealed WPW syndrome with three different reciprocal tachycardias due to triple AV nodal pathways.

The Tokushima journal of experimental medicine·1992
Same author

Peptidyl antithrombogenic agents for extracorporeal blood circulation.

The International journal of artificial organs·1992
Same journal

Effects of Trimethoprim on Three Previously Proposed Putative Biomarkers for OCT2/MATE-Mediated Renal Drug-Drug Interactions in Healthy Volunteers.

Clinical pharmacology and therapeutics·2026
Same journal

Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

Clinical pharmacology and therapeutics·2026
Same journal

Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

Clinical pharmacology and therapeutics·2026
Same journal

Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

Clinical pharmacology and therapeutics·2026
Same journal

Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

Clinical pharmacology and therapeutics·2026
Same journal

Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

Clinical pharmacology and therapeutics·2026
See all related articles

Pediatric drug therapy is improving, but sustained efforts are needed to prevent off-label use, especially in resource-limited areas. This highlights the critical intersection of pediatric pharmacology and global child health.

Area of Science:

  • Clinical Pharmacology
  • Global Child Health
  • Pediatric Therapeutics

Background:

  • Children often lack approved medications, leading to 'therapeutic orphan' status.
  • Off-label and off-evidence drug use in pediatrics poses safety and efficacy risks.
  • Resource-scarce regions face escalating challenges due to growing child populations and limited drug options.

Discussion:

  • Sustained efforts are crucial to minimize inappropriate medication use in children.
  • Addressing the needs of therapeutic orphans is paramount for equitable healthcare.
  • The increasing child population in resource-limited settings amplifies the urgency of safe pediatric drug therapy.

Key Insights:

  • Progress in improving pediatric drug therapy is evident but requires continued commitment.

Related Experiment Videos

  • Eliminating off-label/off-evidence drug use is essential for patient safety and treatment effectiveness.
  • The global dimension of pediatric pharmacology is increasingly recognized as a critical public health issue.

    • Outlook:

    • The convergence of pediatric pharmacology and global child health is an emerging field.
    • This interdisciplinary approach addresses a significant unmet societal need on a global scale.
    • Future research and policy should focus on ensuring safe and effective drug use for all children worldwide.